1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology Market Trends
Dendritic Cell Cancer Vaccine Market & Clinical Insight

Dendritic Cell Cancer Vaccine Market & Clinical Insight

  • January 2015
  • 190 pages
  • ID: 4397238
  • Format: PDF
  • By Kuick Research

Summary

Table of Contents

Dendritic cells are branched cells found in lymphoid organs and they are responsible for antigen display and T-cell activation. Antigen display presents the identity of pathogen to T-cells for their identification and elimination from the body. In 1868, Paul Langerhans discovered dendritic cells and thought that they are part of nervous system because of their branched structure. Until 1973 their identity was mistaken, Ralph Steinman and Zanvil Cohn identified them as a new category of White Blood Cells (WBC) with distinct nature, concentration, features and function in immunity. With time, their potential in developing therapeutics was recognized and in past few years some products has been launched by pharmaceutical companies in market.

Different kinds of cancers have different source of origin and mechanism which presents complexities in front of oncologists to develop a broad acting therapeutic for cancer treatment. Dendritic cells are versatile in nature due to which they can be modified by oncologists depending upon the type of cancer under investigation. Based upon the type of tumor associated antibodies, a dendritic cell cancer vaccine can be formulated to target multiple cancers that make them effective for multiple targets. Some clinical trials are investigating these types of dendritic cell cancer vaccine which would help several patients.

The ability of dendritic cell cancer vaccine to develop anti-tumor immunity has been documented in a number of cases. Oncologists have extensively studied the mechanism of dendritic cell cancer vaccine for several years and they been able to modify them according to medical necessities Loading dendritic cells with antigens isolated from tumor cell has been used for cancer vaccines for identifying different categories and sub-categories of a given cancer. Another major role that they perform is the activation of T-helper cells and cytotoxic T-lymphocytes which are mainly responsible for elimination of cancerous cells.

The continuous supply of dendritic cells for modification to develop novel cancer vaccines without losing time is great essence of time. The low availability of dendritic cells has been mostly solved by developing large scale dendrite cell growth facilities. The problem of expressing tumor specific antigens is another problem which is expected to be solved by gene transfer or mRNA transfections. The present research shows that they have better antigen presenting capabilities due to which their potency is expected to increase. This would be able to reduce the present mortality rates, increase longevity and compete effectively with other therapeutics in same cancer categories.

Genetically modified dendritic cell cancer vaccines are superior tool for targeting recalcitrant cancers like brain cancer therapy. Numerous studies have demonstrated their potential in combinatorial approach to effectively tame the growth of brain tumor. The sure curability effect of therapeutics including these vaccines has not been established but their performance is far better than its competitors in same category. The high pace of research and development along with initial positive results in experimental studies is expected to create large market for dendritic cell based cancer vaccines.

The design of dendritic cell cancer vaccine is likely to improve and much emphasis will be on multiple cancer antigen targeting capabilities of a single molecule. Computer technology is helping oncologists to design and run simulations on these hypothetical vaccines to check their effect on cellular machinery even before going to laboratory and consuming precious resources. This technology could also save lots of time by performing analysis on hundreds of probable vaccine candidates in single experiment. However, the results of such dendritic cell cancer vaccines remain elusive in clinical trials which may be marketed if they produce the significant pharmacological effects in eradicating the cancer.



“Dendritic Cell Vaccine Market & Clinical Insight” Report Highlights:

Introduction & Mechanism of Dendritic Cell Cancer Vaccines
Dendritic Cell Vaccine Market Overview
Market Dynamics (Drivers, Challenges & Future Prospects)
Clinical Pipeline Insight by Phase, Indication & Company
Dendritic Cell Cancer Vaccine in Clinical Pipeline: 52
Majority of Dendritic Cell Cancer Vaccine in Phase-II: 13
Marketed Dendritic Cell Cancer Vaccine: 3 (CreaVax, Provenge & DC-CIK)

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Metastatic Transitional (Urothelial) Tract Cancer Global Clinical Trials Review, H2, 2019

Metastatic Transitional (Urothelial) Tract Cancer Global Clinical Trials Review, H2, 2019

  • $ 2500
  • December 2019

Metastatic Transitional (Urothelial) Tract Cancer Global Clinical Trials Review, H2, 2019Summaryclinical trial report, “Metastatic Transitional (Urothelial) Tract Cancer Global Clinical Trials Review, ...

Acute Respiratory Distress Syndrome - Pipeline Review, H1 2020

Acute Respiratory Distress Syndrome - Pipeline Review, H1 2020

  • $ 2000
  • January 2020

Acute Respiratory Distress Syndrome - Pipeline Review, H1 2020SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H1 2020, provides ...

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2019

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2019SummaryPharmaceutical and Healthcare disease pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H2 2019, provides an overview ...


ref:plp2015

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on